Agency
Medtrans Behavioral Nevada Casal, PLLC
Medtrans Behavioral Nevada Casal, PLLC was paid $26.44M by Medicaid between Jul 2019 and Dec 2024, across 84 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 19% of everything it billed.
33Billing provider infoMEDTRANS BEHAVIORAL NEVADA CASAL, PLLC
RENO, NV 89502
RENO, NV 89502
33aNPI1245781160assigned 10/14/2016
33bProvider typeCommunity/Behavioral Health Agency
28Total paid$26.44M
24GClaims464,537
24DCodes billed84
24AFirst – last monthJul 2019 – Dec 2024
Compared with peers
Next to other Community/Behavioral Health Agency providers in Nevada
Rank by total paid#1 of 358
Median peer was paid$382K
This provider vs. median69×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 700 | $16K | |
| 2020 | 10,128 | $415K | |
| 2021 | 62,183 | $2.40M | |
| 2022 | 151,044 | $7.85M | |
| 2023 | 144,666 | $9.24M | |
| 2024incomplete | 95,816 | $6.52M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 19% | 73,672 | 64,033 | $4.97M |
| T1016 | Case management, each 15 minutes | 17% | 124,097 | 56,965 | $4.53M |
| S9480 | Intensive outpatient psychiatric services, per diem | 13% | 19,348 | 4,273 | $3.31M |
| S5102 | Adult day care, billed per dayDay care services, adult; per diem | 8.1% | 11,093 | 7,641 | $2.13M |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 6.5% | 9,818 | 9,222 | $1.73M |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 6.2% | 16,964 | 10,013 | $1.64M |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 6.1% | 43,637 | 38,614 | $1.60M |
| 99490 | Ccm add 20min | 3.2% | 35,292 | 31,832 | $858K |
| 90792 | Psychiatric diagnostic evaluation with medical services | 2.3% | 6,756 | 6,351 | $613K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | 2.1% | 4,405 | 819 | $549K |
| T2001 | Non-emergency transportation; patient attendant/escort | 1.5% | 31,225 | 8,281 | $408K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.4% | 3,821 | 3,480 | $358K |
72 more codes
| 99233 | Hospital visit by a doctor, follow-up day (complex) | 1.3% | 3,706 | $344K |
| 90834 | Psychotherapy session, about 45 minutes | 1.2% | 4,805 | $323K |
| 99223 | Prolong inpt eval add15 m | 1.2% | 1,737 | $309K |
| Q3014 | Telehealth originating site facility fee | 1.0% | 13,951 | $273K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 6,393 | $251K |
| 99495 | <1% | 3,282 | $246K | |
| H0043 | Supported housing, per diem | <1% | 3,177 | $233K |
| H2017 | Psychosocial rehabilitation, billed per 15 minutes | <1% | 3,035 | $231K |
| H0047 | Alcohol and/or other drug abuse services, not otherwise specified | <1% | 1,373 | $226K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 7,083 | $187K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,348 | $142K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,499 | $120K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,071 | $105K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 794 | $85K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,649 | $80K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,507 | $73K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,849 | $72K |
| H2011 | Crisis intervention service, per 15 minutes | <1% | 303 | $59K |
| H0001 | Alcohol and/or drug assessment | <1% | 569 | $57K |
| H2014 | Skills training and development, per 15 minutes | <1% | 1,290 | $52K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,408 | $40K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 764 | $32K |
| 99205 | Prolong outpt/office vis | <1% | 175 | $29K |
| H0031 | Mental health assessment, by non-physician | <1% | 197 | $28K |
| 90868 | <1% | 132 | $25K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,207 | $19K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 310 | $14K |
| 99306 | Prolong nursin fac eval 15m | <1% | 130 | $11K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 118 | $11K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 151 | $10K |
| 82075 | <1% | 1,284 | $9K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 104 | $8K |
| 86580 | <1% | 1,759 | $6K | |
| 99310 | Prolong nursin fac eval 15m | <1% | 76 | $4K |
| G0506 | Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | <1% | 148 | $4K |
| 90839 | <1% | 34 | $3K | |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 153 | $3K |
| 98966 | <1% | 859 | $3K | |
| H0034 | Medication training and support, per 15 minutes | <1% | 149 | $2K |
| 99350 | Prolong home eval add 15m | <1% | 47 | $2K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 14 | $2K |
| 90836 | <1% | 41 | $1K | |
| 99407 | <1% | 174 | $1K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 26 | $1K |
| 99328 | <1% | 14 | $928.94 | |
| 99345 | Prolong home eval add 15m | <1% | 12 | $794.48 |
| 80305 | <1% | 408 | $774.92 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 203 | $668.74 |
| 99349 | <1% | 44 | $576.17 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 20 | $570.00 |
| 81025 | <1% | 111 | $393.12 | |
| 99439 | <1% | 13 | $247.50 | |
| 99406 | <1% | 14 | $131.81 | |
| 80306 | <1% | 387 | $119.76 | |
| 98967 | <1% | 32 | $116.34 | |
| 82962 | <1% | 55 | $62.38 | |
| H0049 | Alcohol and/or drug screening | <1% | 71 | $48.75 |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 466 | $7.08 |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 817 | $0.17 |
| 4000F | 0% | 22 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 22 | $0.00 |
| 3008F | 0% | 95 | $0.00 | |
| 99308 | Subsequent nursing facility care, per day, straightforward | 0% | 17 | $0.00 |
| 1034F | 0% | 25 | $0.00 | |
| 3074F | 0% | 69 | $0.00 | |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 0% | 19 | $0.00 |
| 3079F | 0% | 13 | $0.00 | |
| 90863 | 0% | 279 | $0.00 | |
| H0010 | Alcohol and/or drug services; sub-acute detoxification (residential addiction program inpatient) | 0% | 136 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 34 | $0.00 |
| 3078F | 0% | 51 | $0.00 | |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 79 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGARRAEZ, SYMON (RCM MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Alliance Mental Health Specialists Suba Park Cheng PLLC | Las Vegas, NV | $5.05M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.